-
1
-
-
0025866549
-
Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer
-
for the International Breast Cancer Study Group
-
Gelber RD, Goldhirsch A, Cavalli F, for the International Breast Cancer Study Group. Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 1991; 114: 621-628.
-
(1991)
Ann. Intern. Med.
, vol.114
, pp. 621-628
-
-
Gelber, R.D.1
Goldhirsch, A.2
Cavalli, F.3
-
2
-
-
0027146570
-
Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments
-
for the International Breast Cancer Study Group
-
Gelber RD, Goldhirsch A, Cole BF, for the International Breast Cancer Study Group. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. Control Clin Trials 1993; 14: 485-499.
-
(1993)
Control Clin. Trials
, vol.14
, pp. 485-499
-
-
Gelber, R.D.1
Goldhirsch, A.2
Cole, B.F.3
-
4
-
-
0022873029
-
A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer
-
for the Ludwig Breast Study Group
-
Gelber RD, Goldhirsch A, for the Ludwig Breast Study Group. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986; 4: 1772-1779.
-
(1986)
J. Clin. Oncol.
, vol.4
, pp. 1772-1779
-
-
Gelber, R.D.1
Goldhirsch, A.2
-
5
-
-
0024536390
-
Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis
-
Goldhirsch A, Gelber RD, Simes RJ et al. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. J Clin Oncol 1989; 7: 36-44.
-
(1989)
J. Clin. Oncol.
, vol.7
, pp. 36-44
-
-
Goldhirsch, A.1
Gelber, R.D.2
Simes, R.J.3
-
7
-
-
0343584508
-
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer
-
Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. J Clin Oncol 2001; 19: 2596-2606.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 2596-2606
-
-
Mouridsen, H.1
Gershanovich, M.2
Sun, Y.3
-
8
-
-
0038460245
-
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group
-
Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-2109.
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 2101-2109
-
-
Mouridsen, H.1
Gershanovich, M.2
Sun, Y.3
-
9
-
-
0037252456
-
Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework
-
Mounier N, Ferme C, Fletchner H et al. Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework. Med Decis Making 2003; 23: 54-66.
-
(2003)
Med. Decis. Making
, vol.23
, pp. 54-66
-
-
Mounier, N.1
Ferme, C.2
Fletchner, H.3
-
10
-
-
1542289007
-
A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer
-
Cole BF, Gelber RD, Gelber S, Mukhopadhyay P. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat 2004; 14: 111-124.
-
(2004)
J. Biopharm. Stat.
, vol.14
, pp. 111-124
-
-
Cole, B.F.1
Gelber, R.D.2
Gelber, S.3
Mukhopadhyay, P.4
|